Full-Time

Vice President/Senior Vice President

Head of Program Development

Posted on 7/19/2025

Strand Therapeutics

Strand Therapeutics

51-200 employees

Develops programmable, long-acting mRNA therapeutics

No salary listed

Boston, MA, USA

In Person

Category
Biology & Biotech (3)
, ,
Requirements
  • Bachelor’s degree in a scientific discipline required; Masters, PhD or MD in science a strong plus.
  • 10-15+ years of pharmaceutical/biotechnology industry experience; Experience working in a smaller, fast paced environment highly preferred.
  • Excellent strategic, planning, communication, and people skills related to clinical-stage drug development
  • Demonstrated experience leading project teams (e.g., CMC, non-clinical, regulatory, clinical)
  • Experience building and managing collaborations with scientists, CROs, consultants, pharmaceutical partners and outside organizations.
  • A broad understanding of drug development as evidenced by a track record of significant contributions to INDs and other regulatory submissions (e.g., BLAs, NDAs)
  • Strong leadership skills, which includes experience being part of an executive staff defining the company's mission/direction, providing input for short and long-term strategies and key decisions
  • Strong skills in identifying and resolving critical issues, as well as identifying opportunities.
  • Strong track record in effectively working with senior management
  • Strong organizational and time management skills.
Responsibilities
  • Responsible for the development and oversight of the program strategy and plans for Strand’s lead program, STX-001.
  • Provide leadership to achieve key program objectives
  • Work with internal program leaders, colleagues, as well as consultants to establish priorities, objectives, and timelines toward achieving program goals. Program activities include planning towards milestones, defining clear go/no go decision points, creating scenario analysis, managing critical path activities, resolving conflicts, proactively identifying issues and opportunities.
  • Ensure optimal team effectiveness through collaboration, coaching, and mentoring of team members
  • Establish systems, processes, and tools to facilitate planning, decision making, and team alignment across the programs.
  • Where needed, identify, select, and manage outside service providers and consultants in support of ongoing development programs.
  • Ensure the effective management of project budgets, including budgeting/forecasting, long-range planning, and budget related decision making.
  • Develop and maintain a strong partnership with our internal Head of Regulatory to ensure development and compliance of regulatory strategies at all stages of development and coordinate related activities cross-functionally.
  • Manage relationships with internal Head of Quality to ensure performance of our internal and external Quality Assurance partners and contribute to the development and maintenance of working practices and procedures for GxP regulatory compliance.
  • Manage and mentor junior Program Management employees in overseeing program progress for preclinical and discovery stage projects.

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company Size

51-200

Company Stage

Series B

Total Funding

$256M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • STX-001 Phase 1 showed confirmed complete response and partial responses by April 2025.
  • $153M Series B from Regeneron, Lilly, Amgen funds STX-003 Phase 1 in 2026.
  • New CFO Kunal Bhatia and CMO Jason Luke strengthen leadership for Phase 2 transition.

What critics are saying

  • Regeneron's liblocalcin achieves 62% ORR in refractory melanoma, eroding STX-001 edge.
  • FDA clinical hold on self-replicating RNA like Gritstone's halts STX-001 by Q2 2026.
  • Eli Lilly enforces milestone repayment if STX-001 misses 20% ORR in Q4 2026 readout.

What makes Strand Therapeutics unique

  • STX-001 deploys programmable mRNA with logic circuits sensing diseased cells only.
  • Intratumoral STX-001 produces localized IL-12, activating immunity without systemic toxicity.
  • Platform enables cell-type specific, multi-functional mRNA therapies for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Strand Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Phone/Internet Stipend

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-4%
The Pharma Data
Aug 23rd, 2025
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer

Strand Therapeutics strengthens leadership with appointment of Dr. Jason J. Luke as Chief Medical Officer.

BiopharmaTrend
Aug 11th, 2025
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Kinnevik's Ala Alenazi, Ph.D., will join Strand's board of directors.

Crunchbase
Aug 8th, 2025
The Week's 10 Biggest Funding Rounds: Public Safety Leads, While Healthcare And Fintech Also See Big Deals

Strand Therapeutics, $153M, biotechnology: Boston-based Strand Therapeutics, a developer of mRNA-based therapeutics, raised $153 million in a Series B funding led by Kinnevik.

Business Wire
Aug 8th, 2025
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

BioSpace
Aug 7th, 2025
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds

Strand Therapeutics on Thursday closed a $153 million series B round that will help it advance its pipeline of novel mRNA therapies for cancer and other chronic conditions.

INACTIVE